Inmed Pharmaceuticals Stock Buy Hold or Sell Recommendation
| INM Stock | USD 4.30 0.23 5.08% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding InMed Pharmaceuticals is 'Strong Sell'. The recommendation algorithm takes into account all of InMed Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out InMed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as InMed and provide practical buy, sell, or hold advice based on investors' constraints. InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
InMed |
Execute InMed Pharmaceuticals Buy or Sell Advice
The InMed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on InMed Pharmaceuticals. Macroaxis does not own or have any residual interests in InMed Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute InMed Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
InMed Pharmaceuticals Trading Alerts and Improvement Suggestions
| InMed Pharmaceuticals generated a negative expected return over the last 90 days | |
| InMed Pharmaceuticals has high historical volatility and very poor performance | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.6 M. Reported Net Loss for the year was (7.68 M) with profit before taxes, overhead, and interest of 1.4 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (6.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: InMed Pharmaceuticals Price-to-Free-Cash-Flow NA - GuruFocus.com |
InMed Pharmaceuticals Returns Distribution Density
The distribution of InMed Pharmaceuticals' historical returns is an attempt to chart the uncertainty of InMed Pharmaceuticals' future price movements. The chart of the probability distribution of InMed Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use InMed Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of InMed Pharmaceuticals returns is essential to provide solid investment advice for InMed Pharmaceuticals.
| Mean Return | -0.72 | Value At Risk | -12.08 | Potential Upside | 9.93 | Standard Deviation | 6.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of InMed Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
InMed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as InMed Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading InMed Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 25.0 | Allsquare Wealth Management Llc | 2024-09-30 | 21.0 | Global Retirement Partners, Llc. | 2024-09-30 | 6.0 | The Toronto-dominion Bank | 2024-06-30 | 2.0 | Bfsg, Llc | 2024-06-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Advisornet Financial, Inc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Advisorshares Investments, Llc | 2024-09-30 | 733.3 K | Sabby Management Llc | 2024-06-30 | 307.2 K |
InMed Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.6M) | 1.6M | (1.2M) | 2.7M | (2.3M) | (2.2M) | |
| Free Cash Flow | (7.2M) | (9.8M) | (15.6M) | (7.4M) | (7.0M) | (6.6M) | |
| Depreciation | 162.0K | 120.9K | 511.8K | 596.0K | 604.5K | 634.7K | |
| Other Non Cash Items | 18.6K | 374.2K | 4.5M | (803.0) | 316.8K | 574.5K | |
| Capital Expenditures | 41.9K | 1.7K | 39.1K | 161.8K | 9.3K | 8.8K | |
| Net Income | (8.7M) | (10.2M) | (18.6M) | (7.9M) | (7.7M) | (7.3M) | |
| End Period Cash Flow | 5.8M | 7.4M | 6.2M | 8.9M | 6.6M | 3.3M | |
| Investments | 4.9M | (1.7K) | (673.0K) | (661.8K) | (9.3K) | (9.8K) | |
| Change To Netincome | 1.3M | 742.0K | 5.2M | 634.2K | 570.8K | 542.3K |
InMed Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to InMed Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that InMed Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a InMed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.76 | |
β | Beta against Dow Jones | 0.26 | |
σ | Overall volatility | 6.75 | |
Ir | Information ratio | -0.12 |
InMed Pharmaceuticals Volatility Alert
InMed Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure InMed Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact InMed Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.InMed Pharmaceuticals Fundamentals Vs Peers
Comparing InMed Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze InMed Pharmaceuticals' direct or indirect competition across all of the common fundamentals between InMed Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as InMed Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of InMed Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare InMed Pharmaceuticals to competition |
| Fundamentals | InMed Pharmaceuticals | Peer Average |
| Return On Equity | -0.72 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Profit Margin | (1.67) % | (1.27) % |
| Operating Margin | (1.57) % | (5.51) % |
| Current Valuation | (1.44 M) | 16.62 B |
| Shares Outstanding | 718.08 K | 571.82 M |
| Shares Owned By Insiders | 0.61 % | 10.09 % |
| Shares Owned By Institutions | 9.50 % | 39.21 % |
| Number Of Shares Shorted | 25.85 K | 4.71 M |
| Price To Book | 0.37 X | 9.51 X |
| Price To Sales | 0.67 X | 11.42 X |
| Revenue | 4.6 M | 9.43 B |
| Gross Profit | 1.4 M | 27.38 B |
| EBITDA | (7.06 M) | 3.9 B |
| Net Income | (7.68 M) | 570.98 M |
| Cash And Equivalents | 9.35 M | 2.7 B |
| Cash Per Share | 9.98 X | 5.01 X |
| Total Debt | 962.66 K | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 3.52 X | 2.16 X |
| Book Value Per Share | 1.03 X | 1.93 K |
| Cash Flow From Operations | (6.99 M) | 971.22 M |
| Short Ratio | 0.12 X | 4.00 X |
| Earnings Per Share | 230.40 X | 3.12 X |
| Target Price | 20.0 | |
| Number Of Employees | 13 | 18.84 K |
| Beta | 0.71 | -0.15 |
| Market Capitalization | 3.09 M | 19.03 B |
| Total Asset | 11.82 M | 29.47 B |
| Retained Earnings | (109.08 M) | 9.33 B |
| Working Capital | 6.72 M | 1.48 B |
| Net Asset | 11.82 M |
Note: Acquisition by Adams Eric A of 11400 shares of InMed Pharmaceuticals at 1.753 subject to Rule 16b-3 [view details]
InMed Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as InMed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About InMed Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell InMed Pharmaceuticals? Buying financial instruments such as InMed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having InMed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Personal Services Thematic Idea Now
Personal Services
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Personal Services theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Personal Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out InMed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.